Skip to Content

John V. Heymach, MD, PhD

Present Title & Affiliation

Primary Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
Chairman, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
David Bruton, Jr Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FC9.3065
Phone: 713-792-6363
Fax: 713-792-1220

Education & Training

Degree-Granting Education

1998 Stanford University Medical School, Stanford, CA, MD, Medicine
1996 Stanford University Medical School, Stanford, CA, PHD, Neuroscience
1989 Harvard University, Cambridge, MA, BA, Chemistry

Postgraduate Training

7/2000-6/2003 Clinical Fellowship, Medical Oncology, Dana-Farber/Partners CancerCare Medical Oncology Fellowship Program, Boston, MA, Laboratory Mentor-Judah Folkman, M.D.; Clinical Mentor-Bruce Johnson M.D.
7/1999-6/2000 Clinical Residency, Internal Medicine, Brigham and Women′s Hospital, Boston, MA
7/1998-6/1999 Clinical Internship, Internal Medicine, Brigham and Women′s Hospital, Boston, MA

Board Certifications

1/2005 Medical Oncology, American Board of Internal Medicine
1/2002 Internal Medicine, American Board of Internal Medicine


Academic Appointments

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2009-8/2013
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD. Anderson Cancer Center, Houston, TX, 7/2005-7/2009

Administrative Appointments/Responsibilities

Leader, Lung Cancer Moon Shot Program, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2012-present

Other Appointments/Responsibilities

Co-Leader, Lung Moon Shots Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-present
Member, Pathology Search Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012

Selected Publications

Peer-Reviewed Original Research Articles

1. Cascone T, Heymach JV. Can the Lung Cancer Pie Be Divided into Angiogenic Slices? Clin Cancer Res. e-Pub 7/2015. PMID: 26232370.
2. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 26(7):1476-1480, 7/2015. e-Pub 5/2015. PMID: 26025965.
3. Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer 89(1):76-79, 7/2015. e-Pub 4/2015. PMID: 25982012.
4. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan YH, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. e-Pub 6/2015. PMID: 26069186.
5. Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer. e-Pub 5/2015. PMID: 25975416.
6. Chen L, Heymach JV, Qin FX, Gibbons DL. The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. Oncoimmunology 4(5):e1002731, 5/2015. e-Pub 2/2015. PMCID: PMC4485725.
7. Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Tong P, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clin Cancer Res. e-Pub 4/2015. PMID: 25878335.
8. Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. Br J Cancer 112(7):1199-1205, 3/2015. e-Pub 3/2015. PMCID: PMC4385961.
9. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-1097, 3/2015. e-Pub 3/2015. PMCID: PMC4366901.
10. Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, Chen K, Futreal A, Wang M, Hofstetter W, Mehran R, Rice D, Roth JA, Sepesi B, Swisher SG, Vaporciyan A, Walsh GL, Johnson FM, Fang B. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett 357(1):179-85, 2/2015. e-Pub 11/2014. PMCID: PMC4301580.
11. Tong P, Coombes KR, Johnson FM, Byers LA, Diao L, Liu DD, Lee JJ, Heymach JV, Wang J. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics. e-Pub 1/2015. PMID: 25600946.
12. Fang B, Mehran RJ, Heymach JV, Swisher SG. Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer 34(1):26, 2015. e-Pub 7/2015. PMID: 26134262.
13. Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics 15:1079, 2014. e-Pub 12/2014. PMCID: PMC4298954.
14. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II,Heymach, JV, Powis G. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. J Natl Cancer Inst 104(3):228-239, 2/2012. e-Pub 1/2012. PMCID: PMC3274509.
15. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach, JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 1/2012. e-Pub 4/2011. PMCID: PMC3276320.
16. Shirvani SM, Komaki R, Heymach, JV, Fossella FV, Chang JY. Positron Emission Tomography/Computed Tomography-Guided Intensity-Modulated Radiotherapy for Limited-Stage Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 82(1):e91-97, 1/2012. e-Pub 4/2011. PMID: 21489716.
17. He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba II, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 7(2):e31087, 2012. e-Pub 2/2012. PMCID: PMC3277494.
18. Coleman RL, Duska LR, Ramirez PT, Heymach, JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 12(12):1109-1117, 11/2011. e-Pub 10/2011. PMID: 21992853.
19. Larsen JE, Cascone T, Gerber DE, Heymach, JV, Minna JD. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 17(6):512-527, Nov-Dec, 11/2011. PMCID: PMC3381956.
20. Lieu C, Heymach, JV, Overman M, Tran H, Kopetz S. Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Anti-Angiogenesis. Clin Cancer Res 17(19). e-Pub 9/2011. PMID: 21953501.
21. Morgillo F, Cascone T, D'Aiuto E, Martinelli E, Troiani T, Saintigny P, De Palma R, Heymach, JV, Berrino L, Tuccillo C, Ciardiello F. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br J Cancer 105(3):382-392, 7/2011. e-Pub 7/2011. PMCID: PMC3172903.
22. Heymach, JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT, Yan S, Dewhirst MW, Kunnamakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diet on plasma levels of NF-{kappa}B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila). e-Pub 7/2011. PMID: 21764858.
23. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach, JV* (co-senior author), Wistuba II* (co-senior author). Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Res. e-Pub 7/2011. PMCID: PMC3159530.
24. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, Deangelis L, Camphausen K, Chen A, Yung W, Prados M, Wen PY, Heymach, JV. Myeloid Biomarkers Associated with Glioblastoma Response to Anti-Vascular Endothelial Growth Factor Therapy with Aflibercept. Clin Cancer Res 17(14):4872-4881, 7/2011. e-Pub 6/2011. PMCID: PMC3139700.
25. Xie Y, Xiao G, Coombes K, Behrens C, Solis LM, Raso MG, Girard L, Erickson HS, Roth JA,Heymach, JV, Moran C, Danenberg KD, Minna JD, Wistuba II. Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non-Small-Cell Lung Cancer Patients. Clin Cancer Res. e-Pub 7/2011. PMCID: PMC3166982.
26. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach, JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Caner. Cancer Discovery 1(1):44-53, 2011 June, 6/2011. PMID: 22586319.
27. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, Byers LA, Heymach JV, Story MD, Lee JJ, Sturgis EM, Weber RS, Garden AS, Ang KK, Schwartz DL. DNA Repair Biomarker Profiling of Head & Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death Following Radiotherapy. Clin Cancer Res 17(7):2035-2043, 4/2011. e-Pub 2/2011. PMCID: PMC3092475.
28. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121(4):1313-1328, 4/2011. e-Pub 3/2011. PMCID: PMC3070607.
29. Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN. Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro. Clin Cancer Res 17(7):1815-1827, 4/2011. e-Pub 2/2011. PMCID: PMC3074405.
30. Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, Heymach JV, Creighton CJ, Kurie JM. miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1. Mol Cancer Res 9(1):25-35, 1/2011. e-Pub 11/2010. PMCID: PMC3232024.
31. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 5(12):1894-1904, 12/2010. PMCID: PMC3374718.
32. Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach JV, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res 70(16):6477-6485, 8/2010. e-Pub 7/2010. PMCID: PMC2922434.
33. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11(7):619-626, 7/2010. e-Pub 6/2010. PMID: 20570559.
34. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-1763, 6/2010. e-Pub 6/2010. PMCID: PMC2913168.
35. Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer 116(10):2465-2475, 5/2010. e-Pub 3/2010. PMID: 20225331.
36. Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18):2616-2627, 5/2010. e-Pub 2/2010. PMID: 20154724.
37. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29(20):2938-2949, 5/2010. e-Pub 3/2010. PMID: 20208561.
38. Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116(7):1751-1756, 4/2010. e-Pub 1/2010. PMCID: PMC2847062.
39. Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70(6):2171-2179, 3/2010. e-Pub 3/2010. PMID: 20215520.
40. Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28(2):193-201, 1/2010. e-Pub 11/2009. PMCID: PMC3040010.
41. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3):453-459, 1/2010. e-Pub 12/2009. PMCID: PMC2815707.
42. Wang J, Byers LA, Yordy JS, Liu W, Shen L, Baggerly KA, Giri U, Myers JN, Ang KK, Story MD, Girard L, Minna JD, Heymach JV, Coombes KR. Blasted Cell Line Names. Cancer Inform 9:251-255, 2010. e-Pub 10/2010. PMCID: PMC2978931.
43. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15(22):6852-6861, 11/2009. e-Pub 10/2009. PMCID: PMC2935176.
44. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG, Wong KK. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 119(8):2160-2170, 8/2009. PMCID: PMC2719950.
45. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-3609, 5/2009. e-Pub 5/2009. PMID: 19447868.
46. Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115(10 Suppl):2346-2354, 5/2009. PMID: 19402074.
47. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15(10):3484-3494, 5/2009. e-Pub 5/2009. PMCID: PMC2893040.
48. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ. Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res 69(5):1836-1843, 3/2009. e-Pub 2/2009. PMID: 19244104.
49. William WN, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 8(3):213-225, 3/2009. PMID: 19247304.
50. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15(1):267-273, 1/2009. PMID: 19118054.
51. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23):3747-3758, 12/2008. e-Pub 12/2008. PMCID: PMC2757147.
52. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407-5415, 11/2008. e-Pub 10/2008. PMID: 18936474.
53. Kim S, Lee S, Greene AK, Arsenault DA, Le H, Meisel J, Novak K, Flynn E, Heymach JV, Puder M. Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib. J Surg Res 149(1):115-119, 9/2008. e-Pub 11/2007. PMID: 18374947.
54. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 359(13):1367-1380, 9/2008. PMID: 18815398.
55. Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 216(3):698-707, 9/2008. PMID: 18381602.
56. Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol 3(6 Suppl 2):S131-134, 6/2008. PMID: 18520296.
57. Ren W, Korchin B, Zhu QS, Wei C, Dicker A, Heymach J, Lazar A, Pollock RE, Lev D. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin Cancer Res 14(9):2785-2795, 5/2008. PMID: 18451246.
58. Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 76(1):15-22, 5/2008. e-Pub 3/2008. PMID: 18440031.
59. Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach JV, Perrone F, Rosell R, Shepherd FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 3(4):430-440, 4/2008. PMID: 18379366.
60. Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-Mckay P, Ryan A, Folkman J, Ryeom S, Heymach J,. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 7(2):418-24, 2/2008. e-Pub 2/2008. PMID: 18245671.
61. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67(24):11924-11932, 12/2007. PMID: 18089823.
62. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25(27):4270-4277, 9/2007. PMID: 17878479.
63. Beaudry P, Hida Y, Udagawa T, Alwayn IP, Greene AK, Arsenault D, Folkman J, Heymach JV, Ryeom S, Puder M. Endothelial progenitor cells contribute to accelerated liver regeneration. J Pediatr Surg 42(7):1190-1198, 7/2007. PMID: 17618879.
64. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 13(14):4035-4041, 7/2007. PMID: 17634526.
65. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13(9):2643-2650, 5/2007. PMID: 17473195.
66. Sakurai MK, Lee S, Arsenault DA, Nose V, Wilson JM, Heymach JV, Puder M. Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. Am J Physiol Lung Cell Mol Physiol 292(3):L742-747, 3/2007. e-Pub 11/2006. PMID: 17122356.
67. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67(1):281-288, 1/2007. PMID: 17210709.
68. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24(22):3555-3561, 8/2006. PMID: 16877721.
69. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):4441s-4445s, 7/2006. PMID: 16857825.
70. Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 12(14 Pt 2):4365s-4371s, 7/2006. PMID: 16857812.
71. Celik I, Sürücü O, Dietz C, Heymach JV, Force J, Höschele I, Becker CM, Folkman J, Kisker O. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65(23):11044-11050, 12/2005. PMID: 16322254.
72. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 11(2 Pt 1):678-689, 1/2005. PMID: 15701856.
73. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10(17):5732-5740, 9/2004. PMID: 15355900.
74. Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF, De Porre PM, Richards HM, Jia X, Zhang S, Johnson BE. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 15(8):1187-1193, 8/2004. PMID: 15277257.
75. Johnson BE, Heymach JV. Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res 10(12 Pt 2):4254s-4257s, 6/2004. PMID: 15217969.
76. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP, Folkman J, Soker S. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 63(23):8345-8350, 12/2003. PMID: 14678995.
77. Kieran MW, Folkman J, Heymach J. Angiogenesis inhibitors and hypoxia. Nat Med 9(9):1104; author reply 1104-1105, 9/2003. PMID: 12949515.
78. Klein RL, Muir D, King MA, Peel AL, Zolotukhin S, Möller JC, Krüttgen A, Heymach JV, Muzyczka N, Meyer EM. Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience 90(3):815-821, 3/1999. PMID: 10218782.
79. Krüttgen A, Möller JC, Heymach JV, Shooter EM. Neurotrophins induce release of neurotrophins by the regulated secretory pathway. Proc Natl Acad Sci U S A 95(16):9614-9619, 8/1998. PMCID: PMC21387.
80. Möller JC, Krüttgen A, Heymach JV, Ghori N, Shooter EM. Subcellular localization of epitope-tagged neurotrophins in neuroendocrine cells. J Neurosci Res 51(4):463-472, 2/1998. PMID: 9514200.
81. Heymach JV, Krüttgen A, Suter U, Shooter EM. The regulated secretion and vectorial targeting of neurotrophins in neuroendocrine and epithelial cells. J Biol Chem 271(41):25430-25437, 10/1996. PMID: 8810312.
82. Heymach JV, Shooter EM. The biosynthesis of neurotrophin heterodimers by transfected mammalian cells. J Biol Chem 270(20):12297-12304, 5/1995. PMID: 7744882.
83. Heymach JV, Barres BA. Neurobiology. Neuronal self-reliance. Nature 374(6521):405-406, 3/1995. PMID: 7700345.
84. Suter U, Heymach JV, Shooter EM. Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF. EMBO J 10(9):2395-2400, 9/1991. PMCID: PMC452934.

Invited Articles

1. Cascone T, Heymach, JV. Targeting the angiopoietin/tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncol 30(4):441-444, 2/2012. e-Pub 12/2011. PMID: 22184396.
2. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol 3(6 Suppl 2):S107-112, 6/2008. PMID: 18520291.
3. Naumov GN, Heymach J, Akslen LA. Dr. Folkman's legacy-a life of angiogenesis research. APMIS 116(2):89-92, 2/2008. PMID: 18321358.
4. Hoque A, Parnes HL, Stefanek ME, Heymach JV, Brown PH, Lippman SM. Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res 67(19):8989-8993, 10/2007. e-Pub 9/2007. PMID: 17895292.
5. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 13(15 Pt 2)(15 Pt 2):s4583-4588, 8/2007. PMID: 17671145.
6. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 13(15 Pt 2):s4617-4622, 8/2007. PMID: 17671152.
7. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 8 Suppl 2:S79-85, 2/2007. PMID: 17382029.
8. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16(2):239-249, 2/2007. PMID: 17243944.
9. Lee D, Heymach JV. Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 7(5):304-308, 3/2006. PMID: 16640800.
10. Heymach JV. ZD6474--clinical experience to date. Br J Cancer 92 Suppl 1:S14-20, 6/2005. PMCID: PMC2362057.
11. Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol 13(4):261-269, 7/2001. PMID: 11429484.
12. Heymach JV Jr, Barres BA. Neurotrophins moving forward [News and Views]. Nature 389:789-791, 1997.


1. Byers LA, Wang J, Diao L, Girard L, Peyton M, Coombes KR, Weinstein JN, Gandhi V, Krett N, Rosen ST, Minna JD, Heymach, JV. An epithelial to mesenchymal transition (EMT) gene expression signature predicts resistance to PI3K/Akt pathway inhibitors in non-small cell lung cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 11/2011.

Book Chapters

1. Heymach JV, Sledge, GW, Jain RK. Tumor Angiogenesis. In: Cancer Medicine, 8th. Ed(s) Hong WK, Bast Jr RC, Hait WN, Kufe DW, Pollock RE, Welchselbaum RR, Holland JF, Frei III E. People's Medical Publishing House-USA: Shelton, CT, 149-169, 2010.
2. Nilsson M B, Hanrahan E O, Heymach JV. Angiogenesis Inhibitors for the Treatment of Lung Cancer. In: Antiangiogenic Agents in Cancer Therapy, 2nd. Ed(s) Teicher BA, Ellis LM. Humana Press: Totwa, NJ, 409-426, 2008.
3. Hanrahan E, Nilsson M, Heymach J. Tumor Angiogenesis: Biology and Therapeutic Implications for Lung Cancer. In: Lung Cancer, 3rd. Ed(s) Roth JA, Cox JD and Hong WK. Blackwell Publishing: Malden, MA, 369-385, 2008.
4. Zurita AJ, Wu HK, Heymach JV. Blood-based biomarkers for VEGF inhibitors. In: Antiangiogenic Cancer Therapy. Ed(s) Davis D W, Herbst R S, Abbruzzese J L. CRC Press: Boca Rotan, FL, 517-531, 2007.
5. Heymach JV. Anti-angiogenic Therapy for Cancer: from the Bench to Bedside and Back. In: AACR Education Book, 177-180, 2006.
6. Folkman J, Heymach J, Kalluri R. Tumor Angiogensis. In: Cancer Medicine, 7th. Ed(s) Kufe DW, Bast Jr RC, Hait WN,Hong WK, Pollock RE, Weichselbam RR, Holland JF, Frei Em. BC Decker Inc: Hamilton, Ontario, 157-191, 2006.
7. Folkman J, Heymach JV, Kalluri R. Tumor Angiogenesis. In: Cancer Medicine. B.C. Decker, 2005.
8. Heymach JV, Folkman J. Tumor Angiogenesis: General Principles and Therapeutic Approaches. In: Tumor Ablation: Principles and Practice. Ed(s) vanSonnenberg E, McMullen WN, Solbiati L. Springer-Verlag Press: New York, NY, 41-55, 2005.
9. Suter U, Drinkwater CC, Heymach JV, Lindsay RM, Shooter EM. Investigations on the structure-function relationship of neurotrophins. In: 15th International Symposium on Brain Sciences. Japan Scientific Society Press, 1992.

Letters to the Editor

1. Kieran, MW, Folkman, J, Heymach JV. Angiogenesis inhibitors and hypoxia [letter]. Nature Medicine 9:2, 2003.
2. Browder T, Folkman J, Hahnfeldt P, Heymach JV, Hlatky L, Kieran M, Rogers MS. Antiangiogenic therapy and p53 [letter]. Science 297:471, 2002.

Grant & Contract Support

Title: Evaluation of circulating plasma biomarkers in patients with advanced NSCLC previously treated with erlotinib in combination with pazopanib (Lun200)
Funding Source: Sarah Cannon Research Institute
Role: Principal Investigator
Duration: 7/15/2011 - 1/14/2014

Last updated: 8/18/2015